KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Merck (MRK) Research & Development (2016 - 2025)

Merck (MRK) has disclosed Research & Development for 17 consecutive years, with $150.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 96.73% to $150.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.1 billion through Dec 2025, down 32.81% year-over-year, with the annual reading at $15.8 billion for FY2025, 11.98% down from the prior year.
  • Research & Development for Q4 2025 was $150.0 million at Merck, down from $4.2 billion in the prior quarter.
  • The five-year high for Research & Development was $13.3 billion in Q2 2023, with the low at $150.0 million in Q4 2025.
  • Average Research & Development over 5 years is $4.1 billion, with a median of $3.9 billion recorded in 2022.
  • The sharpest move saw Research & Development surged 376.09% in 2023, then plummeted 96.73% in 2025.
  • Over 5 years, Research & Development stood at $3.1 billion in 2021, then grew by 23.04% to $3.8 billion in 2022, then surged by 45.7% to $5.5 billion in 2023, then decreased by 16.65% to $4.6 billion in 2024, then tumbled by 96.73% to $150.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $150.0 million, $4.2 billion, and $4.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.